A new series of pyrazolo[3,4-d]pyrimidine/triazine hybrids 6a-r was designed as antitumor and anticonvulsant agents. All the prepared compounds were evaluated against colon (HCT-116), breast (MCF-7) and normal human fibroblast (WI38) cell lines. The most potent derivatives against HCT-116 and MCF-7 cells were 6o and 6q, with IC50 = 4.80 and 6.50 nM, respectively, when compared to lapatinib, the reference
设计了一系列新的
吡唑并[3,4- d ]
嘧啶/三嗪杂化物6a-r作为抗肿瘤和抗惊厥药。所有制备的化合物均针对结肠(HCT-116),乳腺癌(MCF-7)和正常人成纤维细胞(WI38)
细胞系进行了评估。 与参考药物
拉帕替尼相比,针对HCT-116和MCF-7细胞最有效的衍
生物分别为6o和6q,IC 50分别为4.80和6.50 nM( 在HCT-116上,IC 50为12.00和21.00 nM和MCF-7)。所有其他衍
生物均表现出良好至中等的细胞毒活性。四种化合物6f,6j,6o和6q对它们的
EGFR T790M / HER2抑制活性进行评估。他们随后发现对
EGFR T790M和HER2的抑制活性为81.81–65.70%和86.66–54.49%。进一步估计了最有效的衍
生物6o和6q用于细胞周期分析,显示了前G1凋亡活性和细胞生长停滞在G2 / M期。测量了6o和6q的凋亡标记蛋白表达
水平(caspase-3